Liu Ming, Wu Bo, Wang Wen-Zhi, Lee Li-Ming, Zhang Shi-Hong, Kong Ling-Zhi
Stroke Clinical Research Unit, Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Lancet Neurol. 2007 May;6(5):456-64. doi: 10.1016/S1474-4422(07)70004-2.
In this review, we examine the current status of stroke epidemiology, prevention, and management strategies in mainland China. The main findings suggested that total age-adjusted incidence of first-ever stroke in China is not very different from that in developed countries. Stroke incidence, mortality, and prevalence varied widely among different regions within China, with a noticeable north-south gradient. The proportion of intracerebral haemorrhage was high and reached 55% in one city. Hypertension is the most important risk factor for stroke. The mass approach combined with a high-risk approach for stroke prevention showed encouraging effects, and various unconventional local therapeutic traditions are commonly used to treat stroke in China. Several national guidelines on stroke prevention and treatment have been developed. Because of methodological limitations in the epidemiology studies, data are unreliable in terms of making any firm conclusions. Up-to-date, well-designed, and well-done epidemiological studies and therapeutic trials in China are urgently needed.
在本综述中,我们考察了中国大陆地区中风流行病学、预防及管理策略的现状。主要研究结果表明,中国首次中风的年龄调整发病率与发达国家并无太大差异。中风的发病率、死亡率和患病率在中国不同地区差异很大,呈现出明显的南北梯度。脑出血的比例较高,在一个城市达到了55%。高血压是中风最重要的危险因素。大规模方法与针对中风预防的高危方法相结合显示出了令人鼓舞的效果,中国普遍使用各种非传统的地方治疗传统来治疗中风。已经制定了几项关于中风预防和治疗的国家指南。由于流行病学研究存在方法学局限性,在得出任何确凿结论方面数据并不可靠。中国迫切需要开展最新的、设计良好且执行出色的流行病学研究和治疗试验。